Moderna, Inc. — MRNA
| Close Price | Market Cap | P/E Ratio | Forward P/E Ratio | Implied Growth* | Implied Forward Growth* | Dividend | P/B Ratio |
|---|---|---|---|---|---|---|---|
| $40.58 | $15.86B | - | -5.8 | N/A | - | - | 1.7 |
Latest Headlines
- · Moderna (MRNA) Rockets 17% on Strong Preliminary FY25 Results
- · Trending tickers: Nvidia, Intel, Moderna, BP and Vistry
- · Markets Book Profits as Q4 Earnings Season Gets Rolling
- · JPMorgan, Delta, Intel, AMD, Adobe, Moderna, Super Micro, and More Stock Market Movers
- · Stock Market Today: Dow Sinks As Investors Digest Inflation Data; Moderna Soars (Live Coverage)
- · Adobe stock downgraded, Moderna surges on upbeat guidance
Revenue & Net Income
| Date | Revenue | Net Income | EPS | Revenue Change | Net Income Change | EPS Change | |
|---|---|---|---|---|---|---|---|
| 0 | 2020-12-31 | $274.0M | $-747.0M | $-1.96 | N/A | N/A | N/A |
| 1 | 2021-12-31 | $17.7B | $12.2B | $30.31 | 6373.0% | -1733.5% | -1646.4% |
| 2 | 2022-12-31 | $18.9B | $8.4B | $21.26 | 6.4% | -31.5% | -29.9% |
| 3 | 2023-12-31 | $6.8B | $-4.7B | $-12.33 | -64.2% | -156.4% | -158.0% |
| 4 | 2024-12-31 | $3.2B | $-3.6B | $-9.28 | -52.6% | -24.5% | -24.7% |
| 5 | TTM 2025-03-31 | $3.1B | $-3.4B | $-8.73 | -1.9% | -5.7% | -5.9% |
| 6 | Average | 1252.1% | -390.3% | -373.0% |
EPS
Forecasts
Y/Y % Change
MRNA Year-over-Year Growth
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Average | |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth (%) | 6373.0% | 6.4% | -64.2% | -52.6% | -100.0% | inf% | inf% | |
| Revenue Analysts (#) | 0 | 0 | 0 | 0 | 0 | 8 | 8 | |
| EPS Growth (%) | -1733.5% | -31.5% | -156.4% | -24.5% | -12.4% | -13.9% | -328.7% | |
| EPS Analysts (#) | 0 | 0 | 0 | 0 | 0 | 9 | 9 |
Expenses
| Year | Revenue ($) | Cost of Revenue ($) | R&D ($) | SG&A ($) | Facilities / D&A ($) |
|---|---|---|---|---|---|
| 2021 | $17.7B | $2.4B | $2.0B | $567.0M | $232.0M |
| 2022 | $18.9B | $5.1B | $3.3B | $1.1B | $348.0M |
| 2023 | $6.8B | $4.1B | $4.8B | $1.5B | $621.0M |
| 2024 | $3.2B | $1.3B | $4.5B | $1.2B | $189.0M |
| TTM | $2.2B | $947.0M | $3.5B | $1.1B | $208.0M |
| Year | Revenue Change (%) | Cost of Revenue Change (%) | R&D Change (%) | SG&A Change (%) | Facilities / D&A Change (%) |
|---|---|---|---|---|---|
| 2022 | 6.42 | 112.49 | 65.49 | 99.65 | 50.00 |
| 2023 | -64.22 | -19.65 | 47.04 | 36.84 | 78.45 |
| 2024 | -52.64 | -68.69 | -6.23 | -24.21 | -69.57 |
| TTM | -31.17 | -25.73 | -23.42 | -9.63 | 10.05 |
No unmapped expenses.
Balance Sheet
| Metric | Value | |
|---|---|---|
| 0 | Total Assets | $12,010M |
| 1 | Cash | $1,279M |
| 2 | Total Liabilities | $2,611M |
| 3 | Total Debt | $741M |
| 4 | Total Equity | $9,399M |
| 5 | Debt to Equity Ratio | 0.08 |
EPS & Dividend
Valuation
| Share Price | Treasury Yield | Estimates | Fair Value (P/E) | Fair Value (P/S) | Current P/S | Current P/E |
|---|---|---|---|---|---|---|
| $40.58 | 4.1% | Nicks Growth: 8% Nick's Expected Margin: 10% FINVIZ Growth: 21% |
Nicks: 15 Finviz: 46 |
Nick's: 1.460 | 7.2 | - |
| Basis | Year | Nicks Valuation | Nicks vs Share Price | Finviz Valuation | Finviz vs Share Price |
|---|---|---|---|---|---|
| $5.64 Revenue | TTM | $8.23 | -79.7% | $25.93 | -36.1% |
| $5.25 Revenue | 2026 | $7.66 | -81.1% | $24.14 | -40.5% |
Implied Growth
No implied growth data available.